ADMA Biologics Inc  

(Public, NASDAQ:ADMA)   Watch this stock  
Find more results for ADMA
3.04
-0.03 (-0.98%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.16
52 week 2.76 - 7.70
Open 3.15
Vol / Avg. 13,959.00/83,952.00
Mkt cap 78.41M
P/E     -
Div/yield     -
EPS -1.75
Shares 25.79M
Beta 2.11
Inst. own 35%
Nov 8, 2017
Q3 2017 ADMA Biologics Inc Earnings Release (Estimated) Add to calendar
Aug 11, 2017
Q2 2017 ADMA Biologics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -265.83% -183.05%
Operating margin -247.16% -162.56%
EBITD margin - -158.15%
Return on average assets -70.91% -82.34%
Return on average equity -428.34% -
Employees 92 -
CDP Score - -

Address

C/O Adma Biologics Inc., 465 State Route 17
RAMSEY, NJ 07446
United States - Map
+1-201-4785552 (Phone)
+1-201-4785553 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Officers and directors

Steven A. Elms Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Adam S. Grossman President, Chief Executive Officer, Director
Age: 38
Bio & Compensation  - Reuters
Jerrold B. Grossman D.P.S Vice Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Brian Lenz Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
James Mond M.D., Ph.D. Chief Scientific and Medical Officer
Age: 69
Bio & Compensation  - Reuters
Bernhard R. M. Ehmer Director
Age: 62
Bio & Compensation  - Reuters
Bryant E. Fong Independent Director
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Lawrence P. Guiheen Independent Director
Age: 64
Bio & Compensation  - Reuters
Eric I. Richman Independent Director
Age: 55
Bio & Compensation  - Reuters